Vernal Biosciences
Vernal Biosciences is a Vermont-based company dedicated to democratizing access to high-quality mRNA and LNP products for research, development, and clinical applications. They provide integrated CDMO services, including custom synthesis, GMP manufacturing, and analytical services, supporting the entire mRNA therapeutic lifecycle. Their mission is to accelerate the development of mRNA medicines through innovative, scalable, and reliable manufacturing solutions, fostering a collaborative environment to bring life-changing therapies to patients efficiently and effectively.
Industries
Nr. of Employees
medium (51-250)
Vernal Biosciences
Products
Reporter gene mRNAs (e.g., enhanced fluorescent and luciferase reporters)
Research-grade mRNA constructs encoding reporter proteins for assays of translation efficiency, delivery, and biodistribution; designed with optimized codons, modified nucleosides, Cap1 structure, and poly(A) tails.
Gene editing mRNA (e.g., recombinase/Cas9 mRNA formats)
mRNA constructs intended to express gene-editing proteins for transient delivery in cells and animal models.
Gene replacement mRNAs (e.g., therapeutic protein expression constructs)
mRNA constructs designed to express therapeutic proteins (used as gene-replacement models or for proof-of-concept studies).
Antigen mRNAs
mRNA constructs encoding antigenic proteins for use in vaccine research and preclinical immunogenicity studies.
Reporter gene mRNAs (e.g., enhanced fluorescent and luciferase reporters)
Research-grade mRNA constructs encoding reporter proteins for assays of translation efficiency, delivery, and biodistribution; designed with optimized codons, modified nucleosides, Cap1 structure, and poly(A) tails.
Gene editing mRNA (e.g., recombinase/Cas9 mRNA formats)
mRNA constructs intended to express gene-editing proteins for transient delivery in cells and animal models.
Gene replacement mRNAs (e.g., therapeutic protein expression constructs)
mRNA constructs designed to express therapeutic proteins (used as gene-replacement models or for proof-of-concept studies).
Antigen mRNAs
mRNA constructs encoding antigenic proteins for use in vaccine research and preclinical immunogenicity studies.
Services
Design and manufacture of custom high-purity mRNA constructs for research and clinical use, including sequence optimization and modified nucleoside incorporation.
cGMP manufacturing services for mRNA drug substance and LNP-formulated drug product, including clinical supply and sterile fill–finish capabilities.
Formulation development, optimization, and scale-up services for LNP-mRNA, including analytical characterization and stability development.
Analytical method development and testing for plasmid DNA, mRNA, and LNPs to assess critical quality attributes and support regulatory readiness.
Scale-up and manufacturing for larger batch sizes to support late-stage clinical and commercial needs.
Design services for mRNA constructs including codon optimization, modified nucleoside incorporation, cap selection, and poly(A) tail strategies.
Design and manufacture of custom high-purity mRNA constructs for research and clinical use, including sequence optimization and modified nucleoside incorporation.
cGMP manufacturing services for mRNA drug substance and LNP-formulated drug product, including clinical supply and sterile fill–finish capabilities.
Formulation development, optimization, and scale-up services for LNP-mRNA, including analytical characterization and stability development.
Analytical method development and testing for plasmid DNA, mRNA, and LNPs to assess critical quality attributes and support regulatory readiness.
Scale-up and manufacturing for larger batch sizes to support late-stage clinical and commercial needs.
Design services for mRNA constructs including codon optimization, modified nucleoside incorporation, cap selection, and poly(A) tail strategies.
Expertise Areas
- mRNA contract development and manufacturing (CDMO)
- Lipid nanoparticle (LNP) formulation and characterization
- Analytical method development for nucleic acids and nanoparticles
- GMP manufacturing and clinical supply for biologics
Key Technologies
- In vitro transcription (IVT) for mRNA synthesis
- Lipid nanoparticle (LNP) formulation
- Next-generation sequencing (NGS) and long-read sequencing
- Nanopore sequencing
News & Updates
Vernal Biosciences plans to nearly triple its staff from 12 to 35, supported by a Vermont Training Program grant.
Vernal Biosciences is manufacturing mRNA for various pharmaceutical companies beyond vaccines.
Christian Cobaugh, CEO, explains how the company uses DNA in mRNA production.
Construction has started on a new 20,000 sq ft GMP mRNA manufacturing plant in Essex, Vermont.
Vernal has raised $21 million to support high-purity mRNA supply for therapeutics.
Discusses how mRNA-encoded antibodies could accelerate therapies.
Vernal Biosciences plans to nearly triple its staff from 12 to 35, supported by a Vermont Training Program grant.
Vernal Biosciences is manufacturing mRNA for various pharmaceutical companies beyond vaccines.
Christian Cobaugh, CEO, explains how the company uses DNA in mRNA production.
Construction has started on a new 20,000 sq ft GMP mRNA manufacturing plant in Essex, Vermont.
Vernal has raised $21 million to support high-purity mRNA supply for therapeutics.
Discusses how mRNA-encoded antibodies could accelerate therapies.